<DOC>
	<DOCNO>NCT00871338</DOCNO>
	<brief_summary>The purpose Phase II study evaluate feasibility GSK Biologicals ' GSK2197870A vaccine co-administered Wyeth-Lederle 's Prevenar™ give healthy infant three-dose primary vaccination course 2 , 3 4 month age follow booster dose GSK Biologicals ' Menitorix™ 12 month age .</brief_summary>
	<brief_title>Study Evaluate GSK Biologicals ' GSK2197870A Vaccine Given Primary Course Infants</brief_title>
	<detailed_description>This protocol post update follow Protocol amendment 1 , 11-February-2010 ; The Study design section impact amendment .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : A male female infant , include , 6 12 week age time first vaccination . Born 36 42 week gestation . Subjects investigator believe parents/ guardian comply requirement protocol enrol study . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . The following criterion check time study entry . If apply , subject must include study : Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . For corticosteroid , mean prednisone , equivalent , &gt; = 0.5 mg/kg/day . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous intercurrent diphtheria , tetanus , pertussis , poliomyelitis , Hib , pneumococcal and/or group C meningococcal vaccination disease . History seizures progressive neurological disease ( one episode febrile convulsion constitute exclusion criterion ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . The following condition temporary self limit subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness axillary temperature ≥37.5ºC moderate severe illness within 24 hour study vaccine administration</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>combine</keyword>
	<keyword>Vaccines</keyword>
</DOC>